Loading...
Loading...
AMLX| Name | Value |
|---|---|
| Revenues | 108.4M |
| Cost of Revenue | 9.4M |
| Gross Profit | 99.1M |
| Operating Expense | 97.2M |
| Operating I/L | 1.9M |
| Other Income/Expense | 4.5M |
| Interest Income | 4.4M |
| Pretax | 6.5M |
| Income Tax Expense | 1.7M |
| Net Income/Loss | 4.7M |
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their primary product in the pipeline is AMX0035, a dual UPR-Bax apoptosis inhibitor designed for the treatment of ALS. The company also aims to expand the application of AMX0035 to other neurodegenerative diseases, positioning itself as a leader in addressing these challenging medical conditions.
